chartexchange

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Business Wire | Nov 12, 2026 4:05 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026, highlighting recent progress and business updates. “2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350

Read original article